Using procalcitonin to guide duration of antibiotics - further evaluation of the effectiveness

Submission date 14/09/2020	Recruitment status No longer recruiting	[X] Prospectively registered	
		[_] Protocol	
Registration date	Overall study status Completed	[X] Statistical analysis plan	
17/12/2020		[_] Results	
Last Edited 12/09/2024	Condition category Infections and Infestations	Individual participant data	
		[X] Record updated in last year	

Plain English summary of protocol

Background and study aims

In the BATCH trial (https://www.isrctn.com/ISRCTN11369832), researchers are looking at a blood marker for a bacterial infection called procalcitonin to see if it can help to identify how children and young people are responding to antibiotics that are being used to treat the infection. In this study, the researchers would like to see if two other blood markers MR-PRo-adrenomedullin (MR-proADM) and ImmunoXpert can also help provide information that will help treat children and young people with bacterial infection in the future.

Who can participate? Participants recruited into the BATCH trial

What does the study involve?

The researchers would like to collect additional samples of a small amount of blood (0.5-1 ml) from the children and young people recruited into the BATCH trial. They will try to take these samples at the same time as routine blood tests are being taken, or use the leftover blood that is normally discarded by the laboratory after the routine tests are done. However, they may need to take an additional blood test at separate time points if routine bloods are not due to be collected or there is not enough routine blood leftover. The researchers will always ask permission first and will use the method of collection that participants prefer, such as finger prick, vein or arterial line (if this is already in place).

What are the possible benefits and risks of participating?

Participants will be helping to provide information that will help treat children and young people with bacterial infections in the future. They will be given a £20 high street shopping voucher for the inconvenience of participating in the study, which is unconditional and not dependent on giving permission for any additional samples to be taken.

Where is the study run from?

The study is led by the University of Liverpool and managed by the Centre for Trials Research at Cardiff University (UK)

When is the study starting and how long is it expected to run for? September 2020 to August 2024

Who is funding the study? National Institute for Health Research Efficacy and Mechanism Evaluation (NIHR EME) Programme (UK)

Who is the main contact? Dr Cherry-Ann Waldron waldronc@cardiff.ac.uk

Study website http://www.batch-trial.co.uk

Contact information

Type(s) Public

Contact name Dr Cherry-Ann Waldron

ORCID ID http://orcid.org/0000-0001-8465-2492

Contact details

Centre for Trials Research College of Biomedical & Life Sciences Cardiff University 7th Floor Neuadd Meirionnydd Heath Park Cardiff United Kingdom CF14 4YS +44 (0)2929 687609 waldronc@cardiff.ac.uk

Type(s)

Scientific

Contact name Prof Enitan Carrol

Contact details

University of Liverpool Institute of Infection and Global Health Ronald Ross Building 8 West Derby Street Liverpool United Kingdom L69 7BE +44 (0)151 794 9535 edcarrol@liverpool.ac.uk

Additional identifiers

EudraCT/CTIS number Nil known

IRAS number 235042

ClinicalTrials.gov number Nil known

Secondary identifying numbers CPMS 47548, IRAS 235042, UoL001333

Study information

Scientific Title

MR-PRo-adrenomedullin (MR-proADM) and ImmunoXpert Evaluation of procalcitonin-guided antibiotic duration in Children with Infection for Stratification of Effectiveness (PRECISE)

Acronym

PRECISE

Study objectives

The aim of the PRECISE study is to determine if there are specific sub-groups of patients for whom a PCT-guided antibiotic algorithm may be beneficial, harmful or ineffective. It aims to identify endotypes or sub-phenotypes of infection to facilitate optimisation of antibiotic dosing and duration (when, by how much and for how long). The embedded mechanistic study within an existing RCT allows the theranostic exploration of two commercially available biomarker assays to guide judicious antibiotic use.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 13/04/2018, North West Liverpool East Research Ethics Committee (Barlow House, 3rd Floor, 4 Minshull Street, Manchester, M1 3DZ, UK; +44 (0)2071048199; liverpoolcentral. rec@hra.nhs.uk), REC ref: 18/NW/0100

Study design

Embedded mechanism of action study within the BATCH trial (ISRCTN11369832) (a multi-centre, prospective, individually randomised, open-label two-arm randomized controlled trial comparing a PCT-guided antibiotic algorithm versus usual care)

Primary study design

Observational

Secondary study design

Embedded mechanism of action study

Study setting(s)

Hospital

Study type(s) Diagnostic

Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet

Health condition(s) or problem(s) studied

Bacterial infection

Interventions

MR-proADM and ImmunoXpert analysis of blood samples of children recruited to the BATCH trial (ISRCTN11369832) who have been hospitalised with suspected or confirmed bacterial infection, randomised to the intervention arm (e.g. procalcitonin test results that feed into an algorithm that guides antimicrobial prescribing conditions) or the control arm (usual care, no PCT test).

Intervention Type

Other

Primary outcome measure

Collected from patient notes up to and including day 28, or until discharge:

1. Time until IV antibiotic therapy is stopped

2. MR-proADM and ImmunoXpert scores at baseline will define subgroups for the primary comparison, and serial measurements for additional analyses

Secondary outcome measures

Collected from patient notes up to and including day 28, or until discharge:

- 1. Total duration of antibiotics (oral and IV)
- 2. Time to switch from broad-spectrum to narrow-spectrum antibiotics
- 3. Time to discharge from hospital
- 4. Suspected adverse drug reactions measured using the Liverpool Causality Assessment tool
- 5. Hospital-acquired infection up to Day 28

Overall study start date

01/11/2020

Completion date 01/08/2024

Eligibility

Key inclusion criteria

Same as the BATCH trial (ISRCTN11369832)

Participant type(s) Patient

Age group Child

Sex Both

Target number of participants 266

Total final enrolment 407

Key exclusion criteria Same as the BATCH trial (ISRCTN11369832)

Date of first enrolment 01/02/2021

Date of final enrolment 11/10/2022

Locations

Countries of recruitment England

United Kingdom

Study participating centre Alder Hey Children's Hospital Alder Hey Children's NHS Foundation Trust Eaton Road Liverpool United Kingdom L12 2AP

Study participating centre Bristol Royal Hospital for Children University Hospitals Bristol NHS Foundation Trust 24 Upper Maudlin Street Bristol United Kingdom BS2 8BJ

Study participating centre Southampton Children's Hospital, University Hospital Southampton University Hospital Southampton NHS Foundation Trust Tremona Road Southampton United Kingdom SO16 6YD

Study participating centre Children's Hospital, John Radcliffe Hospital Oxford University Hospitals NHS Foundation Trust Oxford United Kingdom OX3 9DU

Sponsor information

Organisation University of Liverpool

Sponsor details

Institute of Infection and Global Health Ronald Ross Building 8 West Derby Street Liverpool England United Kingdom L69 7BE +44 (0)151 794 9535 Sponsor@liverpool.ac.uk

Sponsor type

University/education

Website http://www.liv.ac.uk/

ROR https://ror.org/04xs57h96

Funder(s)

Funder type Government

Funder Name Efficacy and Mechanism Evaluation Programme

Alternative Name(s) NIHR Efficacy and Mechanism Evaluation Programme, EME

Funding Body Type Government organisation

Funding Body Subtype National government

Location United Kingdom

Results and Publications

Publication and dissemination plan

The trialists intend to publish the main trial results in international peer-reviewed journals and present at national and international scientific meetings. A protocol paper will be submitted for publication. Additional documentation will be available upon request.

Intention to publish date

01/02/2025

Individual participant data (IPD) sharing plan

Current Individual participant data (IPD) sharing statement as of 09/02/2023:

The datasets generated during the current study are available upon request from the Centre for Trials Research, Cardiff University by contacting the trial manager at BATCH@cardiff.ac.uk. Pseudo-anonymised data will be provided upon production of the requestor's study protocol and agreement by Centre of Trials Research and study sponsor (University of Liverpool).

Previous Individual participant data (IPD) sharing statement:

The datasets generated during and/or analysed during the current study will be available upon request from opendata@cardiff.ac.uk at the end of the study. The aim is to make the research data available wherever possible, subject to regulatory approvals, any terms and conditions from

external providers, patient confidentiality and all laws concerning the protection of personal information. Data is generally freely available, but recipients are expected to acknowledge the original creators in any public use of the data or in publishing research results based wholly or in part upon the data – anyone requesting access to data will be asked to agree to the terms of the Creative Commons Attribution 4.0 license. The trialists may ask the requestor to cover reasonable cost for preparing and providing the data (for example physical storage and postage, where dataset size makes it impractical to provide data by electronic means).

IPD sharing plan summary

Available on request

Study outputs

Output type	Details SAP article	Date created	Date added	Peer reviewed?	Patient-facing?
<u>Statistical Analysis Plan</u>		30/05/2023	31/05/2023	No	Νο
HRA research summary			28/06/2023	No	No